“Dry Age Macular Degeneration Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Age Macular Degeneration Market.

The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dry Age Macular Degeneration Pipeline Report:

• Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies with a considerable amount of success over the years.

• Dry Age Macular Degeneration companies working in the treatment market are Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Novartis, Alkeus Pharmaceuticals, Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, and others, are developing therapies for the Dry Age Macular Degeneration treatment

• Emerging Dry Age Macular Degeneration therapies in the different phases of clinical trials are- IZERVAY (avacincaptad pegol), SYFOVRE (pegcetacoplan), Iptacopan (LNP023), ALK-001, Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others are expected to have a significant impact on the Dry Age Macular Degeneration market in the coming years.

• Potential therapies expected to drive notable changes during the upcoming forecast period include AVD-104, Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, ANX007, Danicopan (ALXN2040), IONIS-FB-LRx (RG6299), JNJ-1887, CPCB-RPE1, OpRegen, and others.

• In February 2025, Luxa Biotechnology announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). The company is developing this innovative adult retinal pigment epithelial stem cell therapy for patients with dry AMD.

• In November 2024, The U.S. FDA approved LumiThera’s Valeda Light Delivery System for marketing as a treatment for dry age-related macular degeneration (AMD).

Dry Age Macular Degeneration Overview

Dry age-related macular degeneration (AMD) involves a gradual breakdown of macular cells over an extended period. This occurs as retinal cells decline without renewal. It’s important to note that the term ‘dry’ doesn’t imply dry eyes but rather distinguishes it from wet AMD.

Get a Free Sample PDF Report to know more about Dry Age Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight

Emerging Dry Age Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

• IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio

• SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals

• Iptacopan (LNP023): Novartis

• ALK-001: Alkeus Pharmaceuticals

• Tinlarebant (LBS-008): Belite Bio

• XIFLAM: Inflammx Therapeutics

• OCU410: Ocugen

• OLX301A: OliX Pharmaceuticals

• GS030: Gensight Biologics

Dry Age Macular Degeneration Route of Administration

Dry Age Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Dry Age Macular Degeneration Molecule Type

Dry Age Macular Degeneration Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Dry Age Macular Degeneration Pipeline Therapeutics Assessment

• Dry Age Macular Degeneration Assessment by Product Type

• Dry Age Macular Degeneration By Stage and Product Type

• Dry Age Macular Degeneration Assessment by Route of Administration

• Dry Age Macular Degeneration By Stage and Route of Administration

• Dry Age Macular Degeneration Assessment by Molecule Type

• Dry Age Macular Degeneration by Stage and Molecule Type

DelveInsight’s Dry Age Macular Degeneration Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Dry Age Macular Degeneration product details are provided in the report. Download the Dry Age Macular Degeneration pipeline report to learn more about the emerging Dry Age Macular Degeneration therapies

Some of the key companies in the Dry Age Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Dry Age Macular Degeneration are – Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, and others.

Dry Age Macular Degeneration Pipeline Analysis:

The Dry Age Macular Degeneration pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dry Age Macular Degeneration with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.

• Dry Age Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Dry Age Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dry Age Macular Degeneration drugs and therapies

Dry Age Macular Degeneration Pipeline Market Drivers

• Growing geriatric population and rising prevalence of AMD, robust pipeline for dry AMD treatment are some of the important factors that are fueling the Dry Age Macular Degeneration Market.

Dry Age Macular Degeneration Pipeline Market Barriers

• However, lack of awareness about dry AMD, lengthy and expensive clinical trials, lack of early detection and other factors are creating obstacles in the Dry Age Macular Degeneration Market growth.

Scope of Dry Age Macular Degeneration Pipeline Drug Insight

• Coverage: Global

• Key Dry Age Macular Degeneration Companies: Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Novartis, Alkeus Pharmaceuticals, Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, and others

• Key Dry Age Macular Degeneration Therapies: IZERVAY (avacincaptad pegol), SYFOVRE (pegcetacoplan), Iptacopan (LNP023), ALK-001, Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others

• Dry Age Macular Degeneration Therapeutic Assessment: Dry Age Macular Degeneration current marketed and Dry Age Macular Degeneration emerging therapies

• Dry Age Macular Degeneration Market Dynamics: Dry Age Macular Degeneration market drivers and Dry Age Macular Degeneration market barriers

Request for Sample PDF Report for Dry Age Macular Degeneration Pipeline Assessment and clinical trials

Table of Contents

1. Dry Age Macular Degeneration Report Introduction

2. Dry Age Macular Degeneration Executive Summary

3. Dry Age Macular Degeneration Overview

4. Dry Age Macular Degeneration- Analytical Perspective In-depth Commercial Assessment

5. Dry Age Macular Degeneration Pipeline Therapeutics

6. Dry Age Macular Degeneration Late Stage Products (Phase II/III)

7. Dry Age Macular Degeneration Mid Stage Products (Phase II)

8. Dry Age Macular Degeneration Early Stage Products (Phase I)

9. Dry Age Macular Degeneration Preclinical Stage Products

10. Dry Age Macular Degeneration Therapeutics Assessment

11. Dry Age Macular Degeneration Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dry Age Macular Degeneration Key Companies

14. Dry Age Macular Degeneration Key Products

15. Dry Age Macular Degeneration Unmet Needs

16 . Dry Age Macular Degeneration Market Drivers and Barriers

17. Dry Age Macular Degeneration Future Perspectives and Conclusion

18. Dry Age Macular Degeneration Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/